FabI inhibitors (GlaxoSmithKline)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameFabI inhibitors (GlaxoSmithKline)
Drug Alias Name1,4-disubstituted imidazoles (GlaxoSmithKline)FabK inhibitors (GlaxoSmithKline)SB-627696SB-663042SB-633857
ClassificationSmall molecules
Mechanisms of ActionEnzymes inhibitorsLipid metabolism modulators
TargetsEnzymes
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A